Fredun PharmaceuticalsBOM:539730 -2.00%76 Quick Ratio is 0.77 as of Mar. 2026, which is 12% above its 10-year median of 0.69. GuruFocus rates BOM:539730 with a GF Score™ of 76/100 and a GF Value™ of ₹1,585.42 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 996 Drug Manufacturers companies, Fredun Pharmaceuticals ranks worse than 77.21% on this metric.
Fredun Pharmaceuticals has a quick ratio of 0.77. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Fredun Pharmaceuticals's Quick Ratio or its related term are showing as below:
BOM:539730'
s Quick Ratio Range Over the Past 10 Years
Min: 0.47 Med: 0.69 Max: 1.44
Current: 0.77
During the past 13 years, Fredun Pharmaceuticals's highest Quick Ratio was 1.44. The lowest was 0.47. And the median was 0.69.
BOM:539730's Quick Ratio is ranked worse than 77.21% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs BOM:539730: 0.77
Fredun Pharmaceuticals (BOM:539730) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Fredun Pharmaceuticals Quick Ratio Related Terms
Fredun Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Fredun Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fredun Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fredun Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Fredun Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Fredun Pharmaceuticals's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fredun Pharmaceuticals (BOM:539730) has a Quick Ratio of 0.77 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Fredun Pharmaceuticals and its competitors. This is 12% above median its historical median of 0.69. Over the past decade, Fredun Pharmaceuticals' Quick Ratio has ranged from 0.47 to 1.44. According to the industry distribution chart, Fredun Pharmaceuticals ranks #769 out of 996 companies in the Drug Manufacturers industry, placing it in the top 77.2%.
Is Fredun Pharmaceuticals' Quick Ratio too high?
Fredun Pharmaceuticals' current Quick Ratio of 0.77 is 12% above median its 10-year median of 0.69. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 1.44. The Drug Manufacturers industry median Quick Ratio is 1.45. Fredun Pharmaceuticals' value of 0.77 is 46.9% below this industry median. Based on the distribution chart, Fredun Pharmaceuticals ranks #769 out of 996 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Fredun Pharmaceuticals has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fredun Pharmaceuticals' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Fredun Pharmaceuticals ranks #769 out of 996 companies for Quick Ratio. This places Fredun Pharmaceuticals in the lower half of its industry. The industry median Quick Ratio is 1.45. Fredun Pharmaceuticals' value of 0.77 is 46.9% below this benchmark. Historically, Fredun Pharmaceuticals' own Quick Ratio has ranged from 0.47 to 1.44 over the past decade. While the company's 10-year median is 0.69 vs. the industry median of 1.45, Fredun Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fredun Pharmaceuticals's current Quick Ratio of 0.77 is 46.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Fredun Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fredun Pharmaceuticals's current Quick Ratio is 0.77, which is 12% above median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fredun Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fredun Pharmaceuticals (BOM:539730) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,585.42, compared to a current price of ₹2,537.00 — trading 60% above its estimated fair value. The current Quick Ratio is 0.77, which is 12% above median its 10-year median of 0.69 and 46.9% below the Drug Manufacturers industry median of 1.45. Fredun Pharmaceuticals' overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Fredun Pharmaceuticals (BOM:539730), the current Quick Ratio is 0.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fredun Pharmaceuticals (BOM:539730) Overvalued in 2026?
Based on GuruFocus' analysis, Fredun Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,537.00 is trading 60% above its estimated GF Value™ of ₹1,585.42.
GuruFocus considers Fredun Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:539730:
Quick Ratio: 0.77 (12% above median its 10-year median of 0.69)
GF Value™: ₹1,585.42 vs. price of ₹2,537.00 (60% above fair value)
Industry Position: 46.9% below the Drug Manufacturers median (#769 of 996)
No single metric tells the full story. See the BOM:539730 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fredun Pharmaceuticals Ltd in its Endeavour to move ahead has now ventured into manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with Animal Healthcare products also with products ranging from allopathic formulations to on field diagnostic kits, Company's main objective is to be a holistic healthcare provider. The group is dedicated to improving lives of people. The Company operates only in a single segment i.e. Pharmaceutical Segment. The company has presence in Domestic as well as International market. The company generates majority of revenue from Domestic market.
76GF Score
Get the complete analysis for BOM:539730
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539730 has been successfully added to your 
